Market research
GLSI Greenwich Lifesciences Inc
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 245M
- P/E ratio
- Not available
- Analyst target
- 57
- Dividend yield
- Not available
- Beta
- 1.45
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US3968791083
- Market cap
- 245M
- P/E ratio
- Not available
- Analyst target
- 57
- Dividend yield
- Not available
- Beta
- 1.45
About
About Greenwich Lifesciences Inc
Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers in the United States. Its lead product candidate is GP2, a HER2/neu transmembrane peptide, which is in Phase III clinical trial to prevent breast cancer recurrences in patients. The company also develops FLAMINGO-01, which is in Phase IIb and 3 Phase I clinical trial designed to evaluate the safety and efficacy of GLSI-100 in HER2 positive breast cancer patients. Greenwich LifeSciences, Inc. was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. The company was incorporated in 2006 and is headquartered in Stafford, Texas.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the GLSI discussion.
5 years, 4 months ago
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Based on the above factors, Greenwich LifeSciences, Inc gets an overall score of 1/5.